Intractable diseases

Incurable diseases

Nature

Includes both diseases of unknown aetiology, with no established therapeutic remedies (and with the possibility of sequelae), and chronic diseases, which put a heavy social and economic burden on both the patient and the relatives. The definition may be narrowed to include only serious mental and physical disorders (progressive muscular atrophy and dystropy, etc), but may be extended to include: Behcet's disease, multiple sclerosis, myasthenia gravis, and others.

Background

The global significance of intractable diseases emerged in the late 20th century, as medical advances highlighted persistent conditions resistant to conventional therapies. International attention intensified with the HIV/AIDS crisis and the rise of chronic, degenerative illnesses, prompting cross-border research collaborations. Recognition of their socioeconomic impact grew through epidemiological studies and patient advocacy, leading to the establishment of dedicated research initiatives and policy frameworks aimed at addressing the unique challenges posed by these enduring health threats.

Incidence

Intractable diseases, characterized by their resistance to conventional treatments, affect millions globally and impose a significant burden on healthcare systems. Conditions such as amyotrophic lateral sclerosis (ALS), certain forms of cancer, and multidrug-resistant tuberculosis persist despite advances in medical science, leading to prolonged suffering and high mortality rates. The global incidence of these diseases continues to rise, particularly in low- and middle-income countries where access to advanced therapies is limited.
In 2023, Japan reported a notable increase in cases of intractable neurological diseases, including Parkinson’s disease and ALS, with over 1 million patients registered nationwide. This surge has strained healthcare resources and highlighted ongoing challenges in disease management.

Claim

Intractable diseases represent one of humanity’s most urgent and devastating challenges. Their resistance to current treatments inflicts relentless suffering, drains healthcare resources, and shatters families. Ignoring these conditions is both unethical and short-sighted. We must prioritize research, funding, and global collaboration to confront intractable diseases head-on. The world cannot afford complacency—lives are at stake, and the cost of inaction is simply too high.

Counter-claim

Claiming intractable diseases are an important problem is an exaggeration. With so many pressing global issues—poverty, climate change, and education—focusing on diseases that currently have no cure diverts resources from solvable problems. Medical advancements are slow, and pouring effort into the unsolvable is inefficient. Society should prioritize challenges where real progress can be made, rather than obsessing over conditions that, by definition, resist treatment and offer little hope for immediate solutions.